Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glucagon · 1 trial · 1 indication
Rates of pyruvate carboxylase flux and citrate synthesis flux will be assessed using GC/MS and NMR analyses of plasma glucose 13C enrichments after the \[3-13C\]lactate infusion
| Arm | Type | Description |
|---|---|---|
| Glucagon | EXPERIMENTAL | Participants will receive glucagon during the PINTA study |
| Control | EXPERIMENTAL | The same participants will not receive glucagon during the PINTA study |
| Name | Type | Description |
|---|---|---|
| Glucagon | BIOLOGICAL | PINTA study with glucagon |
| Control Study | OTHER | The same participants will not receive glucagon during the PINTA study |
Inclusion Criteria: * Healthy * Non smoking * Taking no medications except birth control Exclusion Criteria: * Any systemic or organ disease * Smoking * Taking any drug or medications other than birth control (women)
Glucagon is being studied in healthy participants to assess its effect on rates of hepatic mitochondrial oxidation in man, as evaluated by the PINTA method. The investigational monoclonal antibody is in Phase 1 clinical development by Merck & Company, Inc. (MRK). One completed trial has been conducted in the United States.
Glucagon is a monoclonal antibody being developed by Merck & Company, Inc. (MRK). The specific molecular target of this investigational drug has not been disclosed in the available clinical trial information. It is being studied for its effects on hepatic mitochondrial oxidation in healthy participants.
Glucagon is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this monoclonal antibody in healthy participants. The investigational drug is currently in Phase 1 development.
Glucagon is in Phase 1 clinical development. It is an investigational monoclonal antibody being studied by Merck & Company, Inc. (MRK). The drug has not been approved by regulatory authorities and remains in clinical trials. One Phase 1 study has been completed.
Glucagon has one completed clinical trial, NCT03965130, titled "The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA." This Phase 1 study enrolled 10 healthy participants in the United States, with a minimum age of 21 years. The trial was controlled but not double-blinded.